Print Page  |  Close Window

SEC Filings

8-K
PROTAGONIST THERAPEUTICS, INC filed this Form 8-K on 03/07/2017
Entire Document
 


PROTAGONIST THERAPEUTICS, INC.

Consolidated Statements of Operations

(In thousands, except share and per share data)

 

     Three Months Ended
December 31,
    Year Ended
December 31,
 
     2016     2015     2016     2015  
     (Unaudited)              

Operating expenses:

        

Research and development

   $ 8,823     $ 4,193     $ 25,705     $ 11,831  

General and administrative

     2,574       808       6,961       2,963  
  

 

 

   

 

 

   

 

 

   

 

 

 

Total operating expenses

     11,397       5,001       32,666       14,794  
  

 

 

   

 

 

   

 

 

   

 

 

 

Loss from operations

     (11,397     (5,001     (32,666     (14,794

Interest income

     149       17       242       19  

Change in fair value of redeemable convertible preferred stock tranche and warrant liabilities

     —         (509     (4,719     (83

Other expense

     —         —         (34     —    
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss

   $ (11,248   $ (5,493   $ (37,177   $ (14,858
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss attributable to common stockholders

   $ (11,248   $ (5,533   $ (37,735   $ (14,933
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss per share attributable to common stockholders, basic and diluted

   $ (0.67   $ (20.31   $ (5.80   $ (59.32
  

 

 

   

 

 

   

 

 

   

 

 

 

Weighted-average shares used to compute net loss per share attributable to common stockholders, basic and diluted

     16,718,242       272,409       6,501,796       251,717